Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587700 | 1.00 | BDKRB1 (0.48) | BDKRB1ROCK2ROCK1NTRK1THRB | |
| SCHEMBL5010845 | 0.89 | ALDH1A1 (0.49) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL14587704 | 0.89 | NTRK1 (0.45) | BDKRB1ROCK2ROCK1NTRK1NPC1 | |
| SCHEMBL14084847 | 0.87 | BDKRB1 (0.62) | BDKRB1THRBNPC1RAB9AKMT2A | |
| SCHEMBL14587720 | 0.86 | BDKRB1 (0.52) | BDKRB1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14587719 | 0.86 | BDKRB1 (0.52) | BDKRB1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14587725 | 0.86 | DCAF1 (0.43) | ROCK2ROCK1NTRK1NPC1RAB9A | |
| SCHEMBL14587724 | 0.86 | DCAF1 (0.43) | ROCK2ROCK1NTRK1NPC1RAB9A | |
| SCHEMBL14587644 | 0.85 | NPC1 (0.41) | NTRK1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5012183 | 0.83 | NPC1 (0.55) | BDKRB1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | BDKRB1 3131/4885ROCK2 3234/4885ROCK1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.